Standard Packaging Crucial for Regulation of Smokeless Tobacco: Experts

Sep.06.2022
Standard Packaging Crucial for Regulation of Smokeless Tobacco: Experts
Bangladesh health experts emphasize the importance of standard packaging for regulating new smokeless tobacco products.

Experts in Bangladesh’s healthcare industry have stated that standard packaging plays a crucial role in regulating the consumption of new and smokeless tobacco products. Smokeless tobacco products pose a harmful threat to public health that is just as significant as the control of cigarette and alcohol consumption, the experts say.


On Monday, during a seminar held at the Six Seasons Hotel in the capital, it was stated that approximately 22 million people in Bangladesh consume smokeless tobacco, which accounts for 58% of the total tobacco consumption in the country.


During a keynote speech at an event organized by the ARK Foundation, York University, and the Health Economics Research Network (HERN), Kamran Siddiqui, Professor of Global Public Health at the Department of Health Sciences at York University, stated that Bangladesh, India, and Pakistan have unusually high rates of smokeless tobacco usage and prevalence in the world.


Despite a slight decline in cigarette consumption rates in Bangladesh over the past few years, the use of smokeless tobacco has remained almost unchanged. Therefore, now is a crucial time to focus on controlling this type of product. This was emphasized by Professor Kamran at a seminar titled "Addressing Smokeless Tobacco Control Policy in Bangladesh.


Kamran Siddiqui has presented several suggestions to control the use of non-combustible tobacco products:


The removal of seasoning products restrictions, the development of standards and monitoring of tobacco-specific nitrosamines (TSNAs), the introduction of retail licenses and viable alternatives, a strict ban on online or social media advertising, community authorization to enforce the ban on sales to minors, increasing taxes, and linking the minimum price to a pack of 20 cigarettes were discussed at an event hosted by Professor AHM Enayet Hossain, former Director General of the Department of Medical Education, with Professor Shakil Ahmed, Director of the National Tuberculosis Control Program, serving as the keynote speaker.


Dr. Syed Mahfuzul Huq, a national expert of the World Health Organization (WHO), participated as a panelist in a project led by Rumana Huque, Executive Director of the ARK Foundation and Professor of Economics at Dhaka University.


During a seminar, a spokesperson revealed that 84% of smokeless tobacco products in Bangladesh do not have appropriate picture health warnings on their packaging. Even if they do have picture health warnings, they do not comply with regulations. They also pointed out that 30% of the packages have no health warnings at all. In neighboring India, the percentage is only 7%.


Furthermore, 16% of tuberculosis patients in Bangladesh are also tobacco consumers. Therefore, experts suggest that controlling tobacco consumption could play a significant role in controlling tuberculosis.


Statement


This article is compiled from third-party information and is intended for industry professionals for the purpose of exchanging knowledge and insights.


This article does not represent the views of 2FIRSTS and 2FIRSTS is unable to confirm the truthfulness and accuracy of its contents. The translation of this article is solely for industry-related exchange and research purposes.


Due to limitations in translation ability, the translated article may not fully reflect the original text. Please refer to the original text for accuracy.


2FIRSTS aligns completely with the Chinese government's remarks and positions regarding any domestic, Hong Kong, Macao, Taiwan, or international affairs.


The copyright of the compiled information belongs to the original media and author, and if there is any infringement, please contact us to delete it.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

 Zyn Emerges as MAGA Cultural Symbol Amid FDA Policy Shift
Zyn Emerges as MAGA Cultural Symbol Amid FDA Policy Shift
According to The Wall Street Journal, nicotine pouch brand Zyn has rapidly gained popularity across the Trump administration and conservative political circles, including among U.S. Health Secretary Robert F. Kennedy Jr.
Business
May.20
PMI U.S. White Paper Calls for Greater Access to FDA-Authorized Smoke-Free Alternatives and Risk-Based Taxation
PMI U.S. White Paper Calls for Greater Access to FDA-Authorized Smoke-Free Alternatives and Risk-Based Taxation
PMI’s U.S. business released a white paper and cited a national online survey showing that 79.00% of Americans surveyed believe more should be done to reduce smoking-related harm. The paper calls on policymakers, public health authorities, and medical professionals to place cigarette smoking back at the center of public health priorities, and recommends broader access to FDA-authorized smoke-free alternatives, clearer nicotine risk communication, and risk-based taxation.
Apr.15 by 2FIRSTS.ai
FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
The U.S. Food and Drug Administration announced on May 6 that it has advanced its modernization initiative by launching Elsa 4.0, an upgraded internal AI tool, and consolidating more than 40 application and submission data sources, systems and portals into a new platform called HALO. FDA said the integration of HALO and Elsa will allow staff to query data and build workflows without manually uploading documents in each chat.
May.07 by 2FIRSTS.ai
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13
Spanish Congress Health Committee Approves Motion to Restrict Vape and Nicotine Pouch Sales to Authorized Channels
Spanish Congress Health Committee Approves Motion to Restrict Vape and Nicotine Pouch Sales to Authorized Channels
Spain’s Congress Health Committee has approved a non-binding motion calling for the sale of vapes, nicotine pouches, and related products to be limited to regulated authorized channels, excluding internet sales and non-specialized stores. The motion was introduced by the Socialist Parliamentary Group and approved after a negotiated text with the Popular Party.
Apr.15 by 2FIRSTS.ai
BAT AGM Highlights Smokeless Strategy, AI Capability and Regulatory Engagement
BAT AGM Highlights Smokeless Strategy, AI Capability and Regulatory Engagement
BAT Chair Luc Jobin told shareholders at the company’s 2026 Annual General Meeting that BAT delivered on its plans in 2025 despite a challenging external environment, with the U.S. business returning to growth, smokeless consumers increasing by more than 15%, improved New Categories contribution, and GBP 6.3 billion returned to shareholders.
Apr.16 by 2FIRSTS.ai